Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism
| Title | Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism |
| Publication Type | Journal Article |
| Year of Publication | 2013 |
| Authors | Fitzgerald DJ, FitzGerald GA |
| Journal | Circ Res |
| Volume | 112 |
| Issue | 1 |
| Pagination | 174-94 |
| Date Published | 2013 Jan 4 |
| ISSN | 1524-4571 |
| Keywords | Animals, Aspirin, Blood Platelets, Cardiovascular Diseases, Cyclooxygenase Inhibitors, Dose-Response Relationship, Drug, Drug Discovery, Drug Resistance, Evidence-Based Medicine, History, 20th Century, History, 21st Century, Humans, Pharmacogenetics, Platelet Aggregation Inhibitors, Purinergic P2Y Receptor Antagonists, Ticlopidine, Translational Medical Research |
| Abstract | The development of drugs that inhibit platelets has been driven by a combination of clinical insights, fundamental science, and sheer luck. The process has evolved as the days of stumbling on therapeutic gems, such as aspirin, have long passed and have been replaced by an arduous process in which a drug is designed to target a specific protein implicated in a well-characterized pathophysiological process, or so we would like to believe. The development of antiplatelet therapy illustrates the importance of understanding the mechanisms of disease and the pharmacology of the compounds we develop, coupled with careful clinical experimentation and observation and, yes, still, a fair bit of luck. |
| DOI | 10.1161/CIRCRESAHA.111.300271 |
| Alternate Journal | Circ. Res. |
| PubMed ID | 23287454 |
| PubMed Central ID | PMC3572712 |
| Grant List | HL062250 / HL / NHLBI NIH HHS / United States U54 HL117798 / HL / NHLBI NIH HHS / United States U54HL117798 / HL / NHLBI NIH HHS / United States |